Masimo is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, including medical devices and a wide array of sensors.

 
 
  • Capnography Solutions
  • Partnering with caregivers and patient monitoring companies to provide a complete portfolio of capnography and gas monitoring solutions
 
  • rainbow® Pulse CO-Oximetry
  • The Masimo rainbow SET™ platform has the unique ability to measure dyshemoglobins and total hemoglobin concentration.
 
 
  • CCHD Screening
  • Reliable, Accurate Screening for Critical Congenital Heart Disease (CCHD) with Masimo SET®

News & Media

 
  • April 10, 2018
  • Irvine, California
  • Masimo (NASDAQ: MASI) announced today the CE marking of the Rad-97™ Pulse CO-Oximeter® with integrated NomoLine™ capnography. With this clearance, Rad-97 is now available both within and outside the U […]
  • April 2, 2018
  • Irvine, California
  • Masimo (NASDAQ: MASI) announced today the release of UniView™, an integrated display of real-time data and alarms from multiple Masimo and third-party devices, designed to reduce clinician cognitive […]
  • March 12, 2018
  • Neuchatel, Switzerland
  • Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Cairo University in Egypt evaluated the accuracy and trending of Masimo noninvasive and continu […]
  • October 2, 2008
  • Masimo SET $1 Million Performance Guarantee
  • In keeping with Masimo’s mission to improve patient care, and to help clinicians separate fact from fiction, Masimo is renewing and expanding its performance guarantee. […]
  • February 23, 2018
  • Patient Safety Movement
  • The Patient Safety Movement Foundation believes reaching ZERO preventable deaths in hospitals by 2020 (0X2020™) is not only the right goal, but an attainable one with the right people, ideas, and tech […]
  • May 1, 2017
  • 2016 Masimo Annual Report
  • 2016 Masimo Annual Report - Through Movement. The first phase of our 10-year plan was to invest in R&D and key functional areas, allowing the company to gain a worldwide presence sufficient to facilit […]

Rad-97, Next Generation SedLine, ISA AX+, and ISA OR+ are not licensed for sale in Canada.
Neonatal NomoLine and ISA products are currently available in the United States only.

Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. See instructions for use for full prescribing information, including indications, contraindications, warnings, and precautions.